Microemulsions for topical delivery of 8-methoxsalen

被引:187
作者
Baroli, B
López-Quintela, MA
Delgado-Charro, MB
Fadda, AM
Blanco-Méndez, J
机构
[1] Univ Santiago de Compostela, Sch Pharm, Dept Farm & Tecnol Farmaceut, Santiago De Compostela 15706, Spain
[2] Univ Cagliari, Sch Pharm, Dept Farmaco Chim Tecnol, I-09124 Cagliari, Italy
[3] Univ Santiago Compostela, Sch Chem, Dept Quim Fis, E-15706 Santiago, Spain
[4] Ctr Interuniv Rech & Enseignement Pharmapeptides, F-74166 Archamps, France
[5] Univ Geneva, Sch Sci, Pharm Galen Lab, CH-1211 Geneva, Switzerland
关键词
methoxsalen; microemulsions; psoriasis; topical delivery; permeation enhancer;
D O I
10.1016/S0168-3659(00)00309-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
8-Methoxsalen (8-MOP) and related furocumarins have been extensively used for the treatment of hyperproliferative skin diseases in association with long-wavelength UVA light. In order to develop alternative formulations for the topical administration of 8-MOP, microemulsions were evaluated as delivery vehicles. Six microemulsion formulations were prepared using water, isopropyl myristate (IPM) and Tween(R) 80. Span(R) 80: 1,2-Octanediol (3:1:1.2 w/w). The microemulsions were characterized using conductimetric and dynamic light scattering analyses. The ability of the systems to deliver 8-MOP into and through the skin was evaluated in vitro using newborn pig-skin. The in vitro permeation data showed that the novel microemulsions increased the 8-MOP total penetration through the skin by order of 1.9-4.5, as compared with IPM. In general, the accumulation of 8-MOP into the skin was increased by a factor of 1.5-4.5 by the microemulsion systems with respect to their total amount of drug delivered across the skin. These results suggest that the studied microemulsion systems may be appropriate vehicles for the topical delivery of 8-MOP. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:209 / 218
页数:10
相关论文
共 25 条
[1]  
*AM PHARM ASS PHAR, 1986, HDB PHARM EXC
[2]   Permeation characteristics of 8-methoxypsoralen through human skin; Relevance to clinical treatment [J].
Anigbogu, ANC ;
Williams, AC ;
Barry, BW .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (04) :357-366
[3]  
[Anonymous], [No title captured]
[4]  
[Anonymous], IND APPL MICROEMULSI
[5]  
BAROLI B, 1998, 16 ADRITELF S PIS IT
[6]  
BAROLI B, UNPUB PHASE DIAGRAM
[7]  
Bourrel M., 1988, Microemulsions and related systems: formulation, solvency, and physical properties
[8]   LIPID MICROEMULSIONS FOR IMPROVING DRUG DISSOLUTION AND ORAL ABSORPTION - PHYSICAL AND BIOPHARMACEUTICAL ASPECTS [J].
CONSTANTINIDES, PP .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1561-1572
[9]   Delivery of a hydrophilic solute through the skin from novel microemulsion systems [J].
DelgadoCharro, MB ;
IglesiasVilas, G ;
BlancoMendez, J ;
LopezQuintela, MA ;
Marty, JP ;
Guy, RH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 43 (01) :37-42
[10]   Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA-bath versus PUVA-cream therapy [J].
Grundmann-Kollmann, M ;
Behrens, S ;
Peter, RU ;
Kerscher, M .
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 1999, 15 (02) :87-89